Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer

Abstract Background We designed a retrospective study to compare prognostic outcomes based on whether or not surgical resection was performed in elderly patients aged(≥75 years) with resectable pancreatic cancer. Methods We retrospectively analyzed 49 patients with resectable pancreatic cancer (surgery group, resection was performed for 38 cases; no surgery group, resection was not performed for 11 cases) diagnosed from January 2003 to December 2014 at the National Cancer Center, Korea. Results There was no significant difference in demographics between the two groups. The surgery group showed significantly better overall survival after diagnosis than the no surgery group (2-year survival rate, 40.7% vs. 0%; log-rank test, p = 0.015). Multivariate analysis revealed that not having undergone surgical resection [hazard ratio (HR) 2.412, P = 0.022] and a high Charlson comorbidity index (HR 5.252, P = 0.014) were independent prognostic factors for poor overall survival in elderly patients with early stage pancreatic cancer. Conclusions In the present study, surgical resection resulted in better prognosis than non-surgical resection for elderly patients with resectable pancreatic cancer. Except for patients with a high Charlson comorbidity index, an aggressive surgical approach seems to be beneficial for elderly patients with resectable pancreatic cancer.

Download Full-text

Retrospective study analysis of the safety and feasibility rates of in patients treated with Nanoknife for locally advanced pancreatic cancer

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.10.266 ◽

2019 ◽

Vol 45 (2) ◽

pp. e73

Author(s):

A. Petrou ◽

V. Lazarou ◽

C. Charalambous ◽

G. Astras ◽

C. Dervenis

Keyword(s):

Pancreatic Cancer ◽

Retrospective Study ◽

Locally Advanced ◽

Advanced Pancreatic Cancer ◽

Locally Advanced Pancreatic Cancer ◽

Study Analysis

Download Full-text

Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study

HPB ◽

10.1016/j.hpb.2019.10.2160 ◽

2019 ◽

Vol 21 ◽

pp. S426

Author(s):

Hyeong Min Park ◽

Sang-Jae Park ◽

Sung-Sik Han

Keyword(s):

Pancreatic Cancer ◽

Retrospective Study ◽

Elderly Patients ◽

Resectable Pancreatic Cancer ◽

Surgical Treatments

Download Full-text

A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01511-0 ◽

2019 ◽

Vol 24 (12) ◽

pp. 1574-1581 ◽

Cited By ~ 7

Author(s):

Rikiya Hasegawa ◽

Kosuke Okuwaki ◽

Mitsuhiro Kida ◽

Hiroshi Yamauchi ◽

Yusuke Kawaguchi ◽

...

Keyword(s):

Pancreatic Cancer ◽

Clinical Trial ◽

Elderly Patients ◽

Advanced Pancreatic Cancer

Download Full-text

Second-line chemotherapy in advanced pancreatic cancer patients before nab-paclitaxel introduction. Retrospective study in Reggio Emilia Clinical Cancer Centre

Annals of Oncology ◽

10.1093/annonc/mdw333.20 ◽

2016 ◽

Vol 27 ◽

pp. iv23

Author(s):

L. Baldi ◽

M. Panebianco ◽

P. Giorgi Rossi ◽

E. Di Felice ◽

T. Cassetti ◽

...

Keyword(s):

Pancreatic Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Advanced Pancreatic Cancer ◽

Reggio Emilia ◽

Second Line ◽

Cancer Centre ◽

Second Line Chemotherapy ◽

Clinical Cancer ◽

Line Chemotherapy

Download Full-text

The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.4_suppl.685 ◽

2020 ◽

Vol 38 (4_suppl) ◽

pp. 685-685 ◽

Cited By ~ 1

Author(s):

Atsushi Oba ◽

Christopher Hanyoung Lieu ◽

Cheryl Lauren Meguid ◽

Sarah Lindsey Davis ◽

Alexis Diane Leal ◽

...

Keyword(s):

Pancreatic Cancer ◽

Elderly Patients ◽

Combination Chemotherapy ◽

Single Agent ◽

Locally Advanced ◽

Neoadjuvant Treatment ◽

Advanced Pancreatic Cancer ◽

Survival Advantage ◽

Locally Advanced Pancreatic Cancer

685 Background: For borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC), neoadjuvant (NAT) FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) are standard treatment options and these regimens have shown a survival advantage over single-agent gemcitabine. However, the role of these modern therapeutic regimens in elderly patients is debatable. In this analysis, we evaluated the outcomes of neoadjuvant treatment (NAT) with combination chemotherapy in elderly patients. Methods: 230 consecutive patients who underwent neoadjuvant treatment for BRPC/LAPC discussed and planned for NAT at the University of Colorado Cancer Center from January 2011 to March 2019 were reviewed. 214 patients who received FOLFIRINOX (n = 143) or GnP (n = 71) were eligible for analysis. We divided all patients into three groups ( < 70, 70-74, ≥75 years) and compared the short-term and long-term outcomes. Results: Of 214 patients, patients < 70 (n = 147) received FOLFIRINOX more frequently than the other groups (p < 0.001): FOLFIRINOX: 115 cases, GnP: 32 cases, 70-74 years (n = 33): FOLFIRINOX: 15 cases, GnP: 18 cases, and ≥75 years (n = 34): FOLFIRINOX: 13 cases, GnP: 21 cases. Resection rates were not statistically different between three groups ( < 70: 62%, 70-74: 70%, ≥75 years: 56%, p = 0.504). There was a slight trend towards worse survival in the two older groups (Median Survival Time [MST]: < 70: 23.2 mo., 70-74: 19.5 mo., ≥75 years: 17.6 mo., p = 0.075) The FOLFIRINOX group was superior to GnP group in all three groups (MST: < 70: 25.6 vs 18.2 mo., p = 0.017; 70-74: 33.2 vs 16.1mo., p = 0.029; ≥75 years: not reached vs 16.1 mo., p = 0.135). There were no toxic deaths or 30 day mortality after pancreatectomy in the study population. Conclusions: Neoadjuvant combination chemotherapy regimens were safe and feasible for elderly patients. Neoadjuvant therapy with FOLFIRINOX was associated with a survival advantage vs GnP and is an good option for fit and elderly patients ≥75 years.

Download Full-text